Table 1. Patient Demographics and Disease Characteristics by Treatment Arm.
| Characteristic | No. (%) | |
|---|---|---|
| Doxorubicin Plus Sorafenib (n = 180) | Sorafenib (n = 176) | |
| Age, median (range), y | 62.0 (21.0-80.0) | 61.5 (30.0-85.0) |
| Gender | ||
| Male | 153 (85.0) | 153 (86.9) |
| Female | 27 (15.0) | 23 (13.1) |
| Race | ||
| Unknown | 3 (1.7) | 6 (3.4) |
| White | 121 (67.2) | 118 (67.0) |
| Black or African American | 24 (13.3) | 26 (14.8) |
| Asian | 27 (15.0) | 23 (13.1) |
| American Indian or Alaska Native | 2 (1.1) | 1 (0.6) |
| Not reported | 3 (1.7) | 2 (1.1) |
| ECOG performance status | ||
| 0 | 65 (36.1) | 70 (39.8) |
| 1 | 111 (61.7) | 100 (56.8) |
| 2 | 4 (2.2) | 6 (3.4) |
| Extent of disease | ||
| Locally advanced | 75 (41.7) | 75 (42.6) |
| Metastatic | 105 (58.3) | 101 (57.4) |
| Hepatitis status | ||
| Missing | 81 (45.0) | 86 (48.9) |
| None | 36 (20.0) | 37 (21.0) |
| Hepatitis B | 16 (8.9) | 17 (9.7) |
| Hepatitis C | 38 (21.1) | 32 (18.2) |
| Hepatitis B and C | 9 (5.0) | 4 (2.3) |
| Histologic grade | ||
| Missing | 3 | 5 |
| Grade cannot be assessed | 33 (18.6) | 39 (22.8) |
| Well differentiated | 41 (23.2) | 39 (22.8) |
| Moderately differentiated | 68 (38.4) | 58 (33.9) |
| Poorly differentiated | 35 (19.8) | 31 (18.1) |
| Undifferentiated | 0 | 4 (2.3) |
| Baseline AFP, median (range), ng/mL | 137.0 (0.0-514 014.0) | 134.4 (0.0-494 082.0) |
| Prior therapy | ||
| Surgery | 47 (26.6) | 51 (29.5) |
| Locoregional therapy | 33 (18.6) | 33 (19.1) |
| Adjuvant | 4 (2.3) | 1 (0.6) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; AFP, alpha-fetoprotein.